TherapeuticsMD Inc
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited - in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(734) | $(3,603) |
| Less: income (loss) from discontinued operations, net of tax | 75 | (1,293) |
| Net loss from continuing operations | (809) | (2,310) |
| Adjustments to reconcile net loss to net cash used in operating activities of continuing operations: | ||
| Depreciation and amortization | 133 | 27 |
| Write-off of patents and trademarks | — | 59 |
| Share-based compensation | 111 | 483 |
| Other | 186 | (60) |
| Changes in operating assets and liabilities: | ||
| Other assets | 629 | (19) |
| Prepaid and other current assets | 34 | (1,453) |
| Accounts payable | 112 | 164 |
| Accrued expenses and other current liabilities | (413) | (4,486) |
| Lease liabilities | (213) | — |
| Other non-current liabilities | 1 | (1,106) |
| Total adjustments | 580 | (6,391) |
| Net cash used in continuing operating activities | (229) | (8,701) |
| Discontinued operations: | ||
| Net cash provided by (used in) operating activities | 240 | (24,474) |
| Net cash provided by financing activities | — | 1,106 |
| Net cash provided by (used in) discontinued operations | 240 | (23,368) |
| Net increase (decrease) in cash | 11 | (32,069) |
| Cash and cash equivalents, beginning of period | 4,327 | 49,317 |
| Total cash and cash equivalents, end of period | $4,338 | $17,248 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.